US Capitol Capsule: Timing or economics? US vulnerable after flu vaccine mismatch
This article was originally published in Scrip
Executive Summary
When US government officials this past summer realized there may potentially be a problem with the effectiveness of the flu vaccine about to be shipped to thousands of doctor offices, health clinics and pharmacies, a question that may be asked by lawmakers at a 3 February Capitol Hill hearing is why manufacturers didn't shift gears and quickly make a vaccine that was better matched to what would become the predominantly circulating A (H3N2) virus.